Item
1. Financial Statements
Interim
Condensed Financial Statements and Notes to Interim Financial Statements
General
The
accompanying unaudited condensed interim financial statements have been prepared in accordance with the instructions to Form 10-Q.
Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results
of operations, cash flows, and stockholders’ deficit in conformity with generally accepted accounting principles. Except
as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included
in the Company’s annual report on Form 10-K for the year ended April 30, 2017. In the opinion of management, all adjustments
considered necessary for a fair presentation of the results of operations and financial position have been included and all such
adjustments are of a normal recurring nature. Operating results for the three months and nine months ended January 31, 2017 are
not necessarily indicative of the results that can be expected for the year ending April 30, 2017.
Omni
Health, Inc.
and
SUBSIDIARIES
Consolidated Balance Sheets
|
|
(unaudited)
January 31,
|
|
|
|
April
30,
|
|
|
|
2017
|
|
|
|
2016
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
Assets
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
$
|
7,649
|
|
|
$
|
21,834
|
|
Accounts
Receivable, Net
|
|
839,393
|
|
|
|
4,708
|
|
Inventory
|
|
286,154
|
|
|
|
26,641
|
|
Other
Receivables and Prepaid Expenses
|
|
150,000
|
|
|
|
3,300
|
|
Total
Current Assets
|
|
1,283,196
|
|
|
|
56,483
|
|
Property,
Plant and Equipment, Net
|
|
301,169
|
|
|
|
1,601
|
|
Cost
Basis Investment
|
|
3,430,973
|
|
|
|
—
|
|
Total
Assets
|
$
|
5,015,338
|
|
|
$
|
58,084
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
Current
Liabilities
|
|
|
|
|
|
|
|
Notes
Payable, Current Portion
|
$
|
901,017
|
|
|
$
|
—
|
|
Accounts
Payable and Accrued Expenses
|
|
295,706
|
|
|
|
2,000
|
|
Due
to mCig, Inc.
|
|
—
|
|
|
|
186,276
|
|
Due
to Related Party
|
|
—
|
|
|
|
2,000
|
|
Total
Current Liabilities
|
|
1,196,723
|
|
|
|
190,276
|
|
Noncurrent
Liabilities
|
|
|
|
|
|
|
|
Bank
loans
|
|
23,968
|
|
|
|
|
|
Due
to Related Party
|
|
573,000
|
|
|
|
—
|
|
Total
Liabilities
|
|
1,793,691
|
|
|
|
190,276
|
|
Stockholders'
Equity
|
|
|
|
|
|
|
|
Common
Stock, $0.0001 par value, voting; 2,000,000,000 shares
|
|
97,583
|
|
|
|
55,455
|
|
authorized;
975,828,741 and 554,551,683 shares issued, and
|
|
|
|
|
|
|
|
outstanding,
as of January 31, 2017 and April 30, 2016
|
|
|
|
|
|
|
|
Treasury
Stock
|
|
(1,052,250
|
)
|
|
|
—
|
|
Shares
issued at spinoff, discount from par value
|
|
—
|
|
|
|
(49,514
|
)
|
Additional
Paid In Capital
|
|
3,834,931
|
|
|
|
435,964
|
|
Accumulated
Deficit
|
|
341,383
|
|
|
|
(574,097
|
)
|
Total
Stockholders' Equity
|
|
3,221,647
|
|
|
|
(132,192
|
)
|
Total
Liabilities and Stockholders' Equity
|
$
|
5,015,338
|
|
|
$
|
58,084
|
|
See
accompanying notes to unaudited consolidated financial statements.
Omni
Health, Inc.
and SUBSIDIARIES
Consolidated Statements of Operations
(unaudited)
|
Three
Months Ended January 31,
|
|
Nine
Months Ended January 31,
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Sales
|
$
|
1,470,844
|
|
|
$
|
39,110
|
|
|
$
|
3,270,794
|
|
|
$
|
117,853
|
|
Total
Cost of Sales
|
|
1,072,701
|
|
|
|
37,473
|
|
|
|
2,366,269
|
|
|
|
85,555
|
|
Gross
Profit
|
|
398,143
|
|
|
|
1,637
|
|
|
|
904,525
|
|
|
|
32,298
|
|
Selling,
general, and administrative
|
|
72,973
|
|
|
|
20,310
|
|
|
|
275,843
|
|
|
|
123,105
|
|
Professional
fees
|
|
16,000
|
|
|
|
5,000
|
|
|
|
21,075
|
|
|
|
18,750
|
|
Payroll
|
|
98,860
|
|
|
|
—
|
|
|
|
187,080
|
|
|
|
—
|
|
Consulting
fees
|
|
249,742
|
|
|
|
—
|
|
|
|
424,945
|
|
|
|
—
|
|
Amortization
and Depreciation
|
|
10,071
|
|
|
|
367
|
|
|
|
17,724
|
|
|
|
1,100
|
|
Total
Operating Expenses
|
|
447,646
|
|
|
|
25,677
|
|
|
|
926,667
|
|
|
|
142,955
|
|
Net
Income(Loss) from operations
|
|
(49,503
|
)
|
|
|
(24,040
|
)
|
|
|
(22,142
|
)
|
|
|
(110,657
|
)
|
Other
(Expense)
|
|
(40,846
|
)
|
|
|
—
|
|
|
|
(143,551
|
)
|
|
|
—
|
|
Net
(Loss) from Continuing Operations
|
|
(90,349
|
)
|
|
|
(24,040
|
)
|
|
|
(165,693
|
)
|
|
|
(110,657
|
)
|
Net
Income from Discontinued Operations
|
|
—
|
|
|
|
—
|
|
|
|
1,081,173
|
|
|
|
—
|
|
Net
Income (Loss)
|
$
|
(90,349
|
)
|
|
$
|
(24,040
|
)
|
|
$
|
915,480
|
|
|
$
|
(110,657
|
)
|
Basic
and Diluted (Loss) Per Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income(Loss)
per share from Continuing Operations
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
0.00
|
|
|
$
|
(0.00
|
)
|
Income(Loss)
Per Share
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
0.00
|
|
|
$
|
(0.00
|
)
|
Weighted
Average Shares Outstanding - Basic and Diluted
|
|
972,228,741
|
|
|
|
503,232,826
|
|
|
|
888,156,755
|
|
|
|
501,683,913
|
|
See
accompanying notes to unaudited consolidated financial statements.
Omni
Health, Inc.
and SUBSIDIARIES
Statements of Cash Flows
(unaudited)
For the Nine Months Ended January 31,
|
2017
|
|
2016
|
Cash
Flows From Operating Activities:
|
|
|
|
|
|
|
|
Net
(Loss)
|
|
915,480
|
|
|
$
|
(110,657
|
)
|
Adjustments
to Reconcile Net Loss to Net
|
|
|
|
|
|
|
|
Cash
Provided By (Used In) Operating Activities:
|
|
|
|
|
|
|
|
Depreciation
and Amortization
|
|
17,724
|
|
|
|
1,100
|
|
Common
stock issued for services
|
|
—
|
|
|
|
57,104
|
|
Decrease
(Increase) in:
|
|
|
|
|
|
|
|
Accounts
Receivable, Net
|
|
(834,685
|
)
|
|
|
(25,215
|
)
|
Inventories
|
|
(259,512
|
)
|
|
|
7,624
|
|
Prepaid
Expenses and Other Current Assets
|
|
(146,700
|
)
|
|
|
—
|
|
Accounts
Payable, Accrued Expenses and Taxes Payable
|
|
293,706
|
|
|
|
(1,500
|
)
|
Deferred
Revenue
|
|
—
|
|
|
|
(35,700
|
)
|
Total
Adjustment to reconcile Net Income to Net Cash
|
|
(947,192
|
)
|
|
|
3,413
|
|
Net
Cash Provided In Operating Activities
|
|
(13,988
|
)
|
|
|
(107,244
|
)
|
Cash
Flows From Investing Activities:
|
|
|
|
|
|
|
|
Increase
(Decrease) in:
|
|
|
|
|
|
|
|
Net
cash received from acquisition
|
|
1,601
|
|
|
|
—
|
|
Net
cash received in investing activities
|
|
1,601
|
|
|
|
—
|
|
Cash
Flows From Financing Activities:
|
|
|
|
|
|
|
|
Proceeds
(Reduction) from issuance of common stock
|
|
(954,215
|
)
|
|
|
—
|
|
Proceeds
from long term loans
|
|
51,457
|
|
|
|
|
|
Proceeds
from short term moans, Net
|
|
605,197
|
|
|
|
—
|
|
Proceeds
(Repayments) to Related Party
|
|
(427,276
|
)
|
|
|
87,693
|
|
Net
Cash Provided By (Used in) Financing Activities
|
|
(724,763
|
)
|
|
|
87,693
|
|
Net
Change in Cash
|
|
(14,185
|
)
|
|
|
(19,551
|
)
|
Cash
at Beginning of Period
|
|
21,834
|
|
|
|
70,516
|
|
Cash
at End of Period
|
$
|
7,649
|
|
|
$
|
50,965
|
|
|
|
|
|
|
|
|
|
Supplemental
Disclosure of Cash Flows Information:
|
|
|
|
|
|
|
|
Cash
paid for interest
|
$
|
140,443
|
|
|
$
|
—
|
|
Cash
paid for income taxes
|
$
|
—
|
|
|
$
|
—
|
|
Inventory
transferred to related party
|
$
|
—
|
|
|
$
|
(2,460
|
)
|
Non-cash
Investing and Financing Activities:
|
|
|
|
|
|
|
|
Net
assets from Malecon Pharmacy Acquisition
|
$
|
3,392,500
|
|
|
$
|
—
|
|
See
accompanying notes to unaudited consolidated financial statements.
OMNI
HEALTH, INC.
Notes
to Condensed Consolidated Financial Statements
(Unaudited)
Note
1 – Organization and Basis of Presentation
The
accompanying audited financial statements of Omni Health, Inc., formerly known as VitaCig, Inc., (the “Company”, “we”,
“our”), have been prepared in accordance with generally accepted accounting principles in the United States of America
and the rules of the Securities and Exchange Commission (“SEC”).
Description
of Business
We
were incorporated in Nevada on January 22, 2014. We began as a technology company that was engaged in the manufacturing
and retailing of nicotine-free Electronic Cigarettes (“eCigs”) that are pre-packaged with vitamins, nutrients, and
generic pharmaceuticals.
The
Company was originally formed as a wholly-owned subsidiary of mCig, Inc. On February 24, 2014 the company entered into a Contribution
Agreement with mCig, Inc. In accordance with this agreement VitaCig, Inc. accepted the contribution by mCig, Inc. of specific
assets consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO and $500 in cash as contribution
in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of the Company.
On
November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc. (the “Spin-off”) (See Note 9: Stockholders’
Equity of the Audited Financial Statement).
On
June 17, 2017 VitaCig acquired Malecon Pharmacy, Inc., in a Stock Exchange Agreement. VitaCig issued LX Retail Group, LLC 575,000,000
common shares of stock in exchange for 100% of the stock of Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., operates as a subsidiary
of VitaCig, Inc. Malecon Pharmacy is a pharmacy that operates in Hialeah, Florida since 1974.
On
June 22, 2017 VitaCig sold its eCig business element to mCig, Inc., in exchange for the return to treasury stock 172,500,000 shares
of VitaCig stock and the reduction of the outstanding amount owed by Vitacig, Inc., to mCig, Inc., in the amount equal to reducing
the outstanding balance to $95,000
. As a result of this transaction, VitaCig, Inc., became
a holding company in which it has one wholly owned subsidiary, Malecon Pharmacy, Inc.
On
September 9, 2017 the company changed its name to Omni Health, Inc.
The
Company currently maintains its corporate office in Haileah, Florida.
Note
2 – Summary of Significant Accounting Policies
The
principal accounting policies are set out below, these policies have been consistently applied to the period presented, unless
otherwise stated:
Use
of Estimates
The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical
experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
The most significant estimates include: sales returns and other allowances; allowance for doubtful accounts; valuation of inventory;
valuation and recoverability of long-lived assets; property and equipment; contingencies; and income taxes.
On
a regular basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted
accordingly. Actual results could differ from those estimates.
Inventory
Prior
to the acquisition of Malecon Pharmacy and the discontinued operations, inventory consisted of finished product, e-Cig products
valued at the lower of cost and net realizable value under the first-in, first-out method of costing. Upon the acquisition of
Malecon Pharmacy, the inventory consisted of prescription drugs, non-prescription drugs and retail merchandise. The Company continues
to value its inventory at the lower of cost and net realizable value under the first-in, first-out method of costing.
Item
|
|
January
31, 2017
|
|
April
30, 2017
|
Prescription
Drugs
|
|
$
|
125,908
|
|
|
$
|
—
|
|
Non-prescription
Drugs
|
|
|
41,244
|
|
|
|
—
|
|
Retail
Merchandise
|
|
|
119,001
|
|
|
|
—
|
|
Finished
Goods
|
|
|
—
|
|
|
|
26,641
|
|
Total
Inventory
|
|
$
|
286,153
|
|
|
$
|
26,641
|
|
Accounts
Receivable
The
Company’s accounts receivable is primarily from its contracts associated with healthcare insurance companies. Under various
agreements, the Company maintains receivables with 17 companies with accounts ranging from 30-90 days. While the company attempts
to collect on all outstanding balances owed, the financial statements do not account for any outstanding receivables beyond 90
days. All receivables beyond 90 days are written off as a drawn down from revenue. Should the company collect at a later date,
which it intends to do, the Company reinstates the revenue during the quarter in which it is paid. Due to the nature of these
funds, the Company expects these receivables to be fully collectible and therefore has not estimated an allowance for doubtful
accounts for the period. The Company did not report any accounts receivable from any of its retail customers. The following table
reflects the accounts receivables as of January 31, 2017.
|
|
Amount
|
|
0-30
days
|
|
|
$
|
284,881
|
|
|
31-60
days
|
|
|
|
259,196
|
|
|
61-90
days
|
|
|
|
295,316
|
|
|
Total
|
|
|
$
|
839,392
|
|
Intangible
assets
The
Company’s intangible assets consist primarily of certain website development costs and are amortized over its estimated
useful life of three years.
Revenue
Recognition
Pharmacy
Services.
We sells prescription drugs directly through our mail service pharmacies, home delivery, and through our retail
pharmacy. We recognize revenues from prescription drugs sold by our mail service and home delivery and the retail pharmacy through
contracts where we are the principal using the gross method at the contract prices negotiated with our customers. Revenue from
Pharmacy Services includes: (i) the portion of the price the customer pays directly to us, net of any volume-related or other
discounts paid back to the customer, (ii) the portion of the price paid to us in a national retail pharmacy network through
the customers insurance plan, and (iii) administrative payments from national retail pharmacy network contracts for incentives
and initiatives.
SEC
Staff Accounting Bulletin 104, “Revenue Recognition, corrected copy” ( “SAB 104”) provides the general
criteria for the timing aspect of revenue recognition, including consideration of whether: (i) persuasive evidence of an
arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the
buyer is fixed or
determinable
and (iv) collectability is reasonably assured. The Company has established the following revenue recognition policies in
accordance with SAB 104:
|
·
|
Revenues
generated from prescription drugs sold by mail service pharmacies are recognized when
the prescription is shipped. At the time of shipment, the Company has performed substantially
all of its obligations under its customer contracts and does not experience a significant
level of reshipments.
|
|
·
|
Revenues
generated from prescription drugs sold through national retail pharmacy network and associated
administrative fees are recognized at the point-of-sale, which is when the claim is adjudicated
by the online claims processing system.
|
We
determine whether we are the principal or agent for our national retail pharmacy network transactions using the indicators set
forth in Emerging Issues Task Force (“EITF”) Issue No. 99-19, “Reporting Revenue Gross as a Principal versus
Net as an Agent” on a contract by contract basis. In all of our current contracts, we have determined we are the principal
due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in establishing the price, changing
the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement
in the determination of product or service specifications and (v) having credit risk. Responsibilities under our customer
contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments
due to the retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the physician prior
to dispensing, suggesting clinically appropriate generic alternatives where appropriate and approving the prescription for dispensing.
Although we do not have credit risk with respect to Retail Co-Payments, management believes that all of the other indicators of
gross revenue reporting are present.
Drug
Discounts ~ We deduct from our revenues any discounts paid to our customers as required by EITF No. 01-9, “Accounting
for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products)” (“EITF 01-9”).
Retail
Pharmacy Segment
~ We recognize revenue from the sale of merchandise (other than prescription drugs) at the time the
merchandise is purchased by the retail customer. Revenue from the sale of prescription drugs is recognized at the time the prescription
is filled, which is or approximates when the retail customer picks up the prescription. Customer returns are not material. Revenue
generated from the performance of services is recognized at the time the services are performed.
Cost
of Goods Sold
The
Company recognizes the direct cost of purchasing product for sale, including freight-in and packaging, as cost of goods sold in
the accompanying income statement.
Financial
Instruments
The
carrying amounts reflected in the balance sheets for cash and due to related parties approximate the respective fair values due
to the short maturities of these items. The Company does not hold any investments that are available-for-sale.
As
required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair
value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted
prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly
or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity
to develop its own assumptions.
The
three levels of the fair value hierarchy are described below:
Level 1
—Valuations
based on quoted prices for identical assets and liabilities in active markets.
Level 2
—Valuations
based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities
in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs
that are observable or can be corroborated by observable market data.
Level 3
—Valuations
based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market
participants. These valuations require significant judgment.
The
Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.
Income
Taxes
Income
taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the
estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets
and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets are
reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the
deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates in effect
for the year in which those temporary differences are expected to be recovered or settled.
Basic
and Diluted Net Income (Loss) Per Share
The
Company follows ASC Topic 260 to account for earnings (loss) per share. Basic earnings (loss) per share (“EPS”)
calculations are determined by dividing net income (loss) by the weighted average number of shares of common stock outstanding
during the three months. Diluted earnings per share calculations are determined by dividing net income by the weighted average
number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents,
if any, are anti-dilutive they are not considered in the computation.
There
is no potential dilutive security as of January 31, 2017 or 2016.
Concentration
of Credit Risk
Financial
instruments, which potentially subject us to concentrations of credit risk, consist principally of cash and trade receivables. Concentrations
of credit risk with respect to trade receivables are limited due to the clients that comprise our customer base and their dispersion
across different business and geographic areas. We estimate and maintain an allowance for potentially uncollectible
accounts and such estimates have historically been within management's expectations.
Our
cash balances are maintained in accounts held by major banks and financial institutions located in the United States. The
Company may occasionally maintain amounts on deposit with a financial institution that are in excess of the federally insured
limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company
had no deposits in excess of federally insured limits at January 31, 2017 and April 30, 2016.
Impairment
of Long-lived Assets
The
Company accounts for long-lived assets in accordance with the provisions of FASB Topic 360, “
Accounting for the Impairment
of Long-Lived Assets
”. This statement requires that long-lived assets and certain identifiable intangibles be reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
An impairment loss would be recognized when the estimated future cash flows from the use of the asset are less than the carrying
amount of that asset. No impairments were recorded during the periods ended January 31, 2017 and 2016.
Warranties
Warranty
reserves include management’s best estimate of the projected costs to repair or to replace any items under warranty, based
on actual warranty experience as it becomes available and other known factors that may impact the Company’s evaluation of
historical data. The Company did not have any significant warranty expenses to report for the three months ended January 31, 2017.
Based on these actual expenses, the warranty reserve, as estimated by management as of January 31, 2017 was at $0. Any adjustments
to warranty reserves are to be recorded in cost of sales.
Recent
Accounting Pronouncements
The
Company evaluated all recent accounting pronouncements issued and determined that the adoption of these pronouncements would not
have a material effect on the financial position, results of operations, or cash flows of the Company.
In
April 2014, the FASB issued ASU 2014-08,
Reporting Discontinued Operations and Disclosures of Components of an Entity
,
which updates the definition of discontinued operations. Going forward, only those disposals of components of an entity that represent
a strategic shift that has (or will have) a major effect on an entity's operations and financial results will be reported as discontinued
operations in the financial statements. Previously, a component of an entity that is a reportable segment, an operating segment,
a reporting unit, a subsidiary, or an asset group was eligible for discontinued operations presentation. Additionally, the condition
that the entity not have any significant continuing involvement in the operations of the component after the disposal transaction
has been removed. The effective date for the revised standard is for applicable transactions that occur within annual periods
beginning on or after December 15, 2014. We do not expect the guidance to have a material impact on the Company.
In
July 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-11 "Simplifying the Measurement
of Inventory"; guidance which requires inventory within the scope of the standard to be measured at the lower of cost and
net realizable value. Previous guidance required inventory to be measured at the lower of cost or market (where market was defined
as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The
updated guidance is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption
permitted. There were various other updates recently issued, none of which are expected to a have a material impact on the Company’s
financial position, results of operations or cash flows.
Note
3. Going Concern
The
Company's financial statements are prepared using generally accepted accounting principles, which contemplate the realization
of assets and liquidation of liabilities in the normal course of business. Because the business is new and has a limited history
and relatively few sales, no certainty of continuation can be stated. The accompanying financial statements for the nine months
and three months ended January 31, 2017 and 2016 have been prepared assuming that the Company will continue as a going concern,
which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The
Company has suffered losses from operations and has a working capital deficit, which raises substantial doubt about its ability
to continue as a going concern.
Management
is taking steps to raise additional funds to address its operating and financial cash requirements to continue operations in the
next twelve months. Management has devoted a significant amount of time in the raising of capital from additional debt and equity
financing. However, the Company’s ability to continue as a going concern is dependent upon raising additional funds through
debt and equity financing and generating revenue. There are no assurances the Company will receive the necessary funding or generate
revenue necessary to fund operations. The financial statements contain no adjustments for the outcome of this uncertainty.
Note
4. Intangible Assets:
|
|
|
As
of
|
|
|
|
April
30, 2017
|
|
Weighted
Average
Useful Life
(in Years)
|
|
Gross
Carrying Amount
|
|
Accumulated
Amortization
|
|
Net
Carrying
Amount
|
|
|
|
$
|
|
$
|
|
$
|
Finite
lived intangible assets
|
|
|
|
|
|
|
Internet
website
|
3
|
|
4,400
|
|
(2,799)
|
|
1,601
|
Total
identifiable intangible assets
|
|
4,400
|
|
(2,799)
|
|
1,601
|
|
Weighted
Average
Useful Life
(in Years)
|
|
Gross
Carrying Amount
|
|
Accumulated
Amortization
|
|
Net
Carrying
Amount
|
|
|
|
$
|
|
$
|
|
$
|
Finite
lived intangible assets
|
|
|
|
|
|
|
Internet
website
|
3
|
|
4,400
|
|
(3,057)
|
|
1,343
|
Total
identifiable intangible assets
|
|
4,400
|
|
(3,057)
|
|
1,343
|
Amortization
expense on intangible assets was $258 and $0 for the nine months and three months period ending January 31, 2017, respectively,
and $1,466 for the year ended April 30, 2017. The intangible asset was sold as part of the Company’s discontinued operation
on June 22, 2017. See Note 10.
Note
5. Notes Payable
The
following table lists the short term and long term notes payable:
Short
Term Notes Payable
|
|
Original
Amount/Assumed Amount
|
|
As
of January 31, 2017
|
Current
portion of the Lending Club
|
10,070
|
|
11,287
|
Small
Business loan
|
|
268,331
|
|
82,371
|
Current
portion of Circle Back Lending
|
|
5,230
|
|
5,914
|
Star
Capital Loan
|
|
1,000,000
|
|
482,863
|
Assumed
Assumed Liabilities
|
|
20,532
|
|
-
|
Due
to mCig
|
|
|
|
|
95,000
|
|
-
|
Accounts
Receivable Factoring
|
|
|
-
|
|
257,125
|
Loan
from Shareholder
|
|
10,000
|
|
10,000
|
Total
Short Term Notes Payable
|
|
1,409,163
|
|
849,560
|
Long
Term Notes Payable
|
|
|
|
|
|
|
The
Lending Club
|
23,376
|
|
15,534
|
Circle
Back Lending
|
|
12,448
|
|
8,434
|
Loan
from Shareholder
|
|
812,000
|
|
573,000
|
Total
Long Term Notes Payable
|
|
847,824
|
|
596,968
|
Total
Notes Payable
|
|
2,256,987
|
|
1,446,528
|
|
|
|
|
|
|
|
|
|
|
As
a part of the discontinue operations of VitaCig the company entered into a convertible promissory note with mCig, Inc., in the
amount of $95,000 on June 6, 2017. The company accrued $3,108 in interest on the promissory note through January 31, 2017 bringing
the total balance due to $98,108. On January 31, 2017 mCig, Inc. elected to convert the promissory note into shares of the company’s
stock. See Note 8.
The
Lending Club loan was executed by Malecon Pharmacy on April 23, 2017 in the amount of $35,000. The company assumed the remaining
balance of $33,446 on June 17, 2017. The note is scheduled to be paid off on March 23, 2019 and has a monthly payment of $1,218.
The
Small Business loan was executed by Malecon Pharmacy on April 22, 2017 in the amount of $300,000. The company assumed the remaining
balance of $161,935 on June 17, 2017. The payment terms of the note are $1,550 each business day for 240 business days. There
was 209 business days left on the note at the time of acquisition and 116 remaining as of January 31, 2017.
The
Circle Back Lending loan was executed by Malecon Pharmacy on April 21, 2017 in the amount of $18,500. The company assumed the
remaining balance of $17,718 on June 17, 2017. The note is scheduled to be paid off on March 21, 2019 and has a monthly payment
of $674.
The
Star Capital loan was executed by the Malecon Pharmacy on June 24, 2017 in the amount of $500,000. The note is scheduled to be
paid off on December 23, 2017 and has a monthly payment of $90,833. In September 2017, the company entered into a second loan
with Star Capital for up to an additional $500,000 in financing. The company has received $350,000. The company recognizes the
remaining amount of $150,000 as other receivable. The company is scheduled to pay off this new loan portion on August 2017 and
has a monthly payment of $49,167.
The
company assumed certain other liabilities and a loan from the shareholder of Malecon Pharmacy in the amount of $30,532 for various
obligations associated with the day-to-day operations of the specialty pharmacy. The company paid $5,243 during the period ending
January 31, 2017 leaving a remaining balance of $6,750 in assumed liabilities and $10,000 due to related party.
Note
6. Related Parties and Related Party Transactions
Details
of balances between the company and related partied are disclosed below:
|
As
of January 31, 2017
|
|
As
of April 30, 2017
|
Loan
from related parties
|
$
|
583,000
|
|
|
$
|
188,276
|
|
The
following entities have been identified as related parties:
LX
Retail Group, Inc. Greater than 10% stockholder.
Malecon
Pharmacy, Inc. Subsidiary company.
Andrey
Soloviev Director and CEO
On
June 22, 2017 when the company acquired Malecon Pharmacy, Inc., it assumed the liability of $812,000 owed to the principal owner
of Malecon Pharmacy, Inc. During the three months and nine months ended January 31, 2017, the company paid $77,000 and $239,000
towards that outstanding balance, respectively, leaving a balance of $573,000 owed.
Note
7. Commitments and Contingencies
The
Company has commitments for three leased facilities. In addition, the Company has a lease commitment for its pharmacy software
system.
|
-
|
The
company headquarters located in Miami Beach, Florida. The office rent is $5,947.41 per
month. The lease expires on May 1, 2019.
|
|
-
|
The
Company Pharmacy building in Hialeah, Florida. The rent for the facility is $8,146.74
per month. The lease expires on February 1, 2017.
|
|
-
|
The
Company Warehouse and Distribution Center in Miami Florida. The company pays $1,605 a
month as rent, which expires August 1, 2017.
|
|
-
|
The
Company has a lease for its QS/1 Data System. The company pays $527.26 per month, which
expires on April 30, 2018.
|
The
following chart shows the Company commitments for the next five years:
|
|
|
|
Year
|
|
|
|
Amount
|
|
|
2017
|
|
|
$
|
48,680
|
|
|
2018
|
|
|
|
178,425
|
|
|
2019
|
|
|
|
81,127
|
|
|
2020
|
|
|
|
71,370
|
|
|
2021
|
|
|
|
5,948
|
|
|
Total
|
|
|
$
|
387,131
|
|
Note
8. Stockholders’ Equity (Deficit)
Common
Stock
The
authorized capital stock of the Company consists of 2,000,000,000 shares of Common Stock, par value $0.0001 per share.
On
February 24, 2014, the Company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement, VitaCig,
Inc. accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the term “VitaCig”
filed with the USPTO on January 18, 2014, and $500 in cash as contribution in exchange for 500,135,000 shares of common capital
stock representing 100% of the shares outstanding of the Company.
On
November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc. (the “Spin-off).
As
of April 30, 2017, the Company was authorized to issue 560,000,000 common shares at a par value of $0.0001. As of April 30, 2016
the Company had issued 500,135,000 common shares. During the year the Company issued 54,416,683 shares of common stock for services
rendered - the price evaluate is $441,405. As of April 30, 2017 the total issued and outstanding of common stock was 554,551,683.
On
June 17, 2017, the Company issued LX Retailers, LLC 575,000,000 shares of the Company’s common stock as the purchase price
for Malecon Pharmacy
.
On
January 31, 2017 mCig elected to convert its promissory note into shares of the company stock. The total amount due at the time
of conversion was $98,108. The company issued 17,677,058.
Note
9. Acquisition of Malecon Pharmacy, Inc.
On
June 17, 2017, the Company and LX Retailers, LLC entered into a share exchange agreement whereby the Company acquired 100% of
the stock of Malecon Pharmacy, Inc., whereby LX Retailers, LLC transferred the assets and operations of the business of Malecon
Pharmacy, Inc., to Company in exchange for 575,000,000 shares of the Company’s Common Stock.
The
purchase price of Malecon Pharmacy, Inc., was $3,392,500. The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed, at the date of acquisition:
Purchase
Price (575,000,000 shares @ $0.0059)
|
|
$
|
3,392,500
|
|
|
|
|
|
|
Cash
|
|
$
|
107,276
|
|
Accounts
Receivable
|
|
|
739,224
|
|
Inventory
|
|
|
256,507
|
|
Medical
Equipment
|
|
|
254,232
|
|
Property,
plant & equipment
|
|
|
64,661
|
|
Cost
basis investment
|
|
|
3,430,973
|
|
Total
assets acquired
|
|
$
|
4,852,873
|
|
|
|
|
|
|
Accounts
Payable
|
|
|
359,510
|
|
Other
Liabilities
|
|
|
20,532
|
|
Small
Business Loan
|
|
|
268,331
|
|
Due
to Related Party
|
|
|
812,000
|
|
Total
liabilities assumed
|
|
|
1,460,373
|
|
Net
assets acquired
|
|
$
|
3,392,500
|
|
In
accordance with ASC 805-10-50, the Company is providing the following unaudited pro-forma to present a summary of the combined
results of the Company’s consolidated operations with the acquisition as if the acquisition had been completed as of the
beginning of the reporting period.
|
|
For
three month ending January 31,
|
|
For
nine months ending January 31,
|
CONSOLIDATED
STATEMENT of OPERATIONS:
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Sales
|
|
$
|
1,470,844
|
|
$
|
1,503,330
|
|
$
|
4,383,034
|
|
$
|
4,804,276
|
Cost
of Sales
|
|
|
1,072,701
|
|
|
1,170,735
|
|
|
2,763,067
|
|
|
3,780,523
|
Gross
Profit
|
|
|
398,143
|
|
|
332,595
|
|
|
1,619,967
|
|
|
1,023,753
|
Operating
Expenses
|
|
|
447,646
|
|
|
315,690
|
|
|
1,026,109
|
|
|
1,662,456
|
(Loss)
from Operations
|
|
|
(49,503)
|
|
|
16,905
|
|
|
593,858
|
|
|
(638,703)
|
Other
Income / (Expense)
|
|
|
(40,846)
|
|
|
-
|
|
|
(143,551)
|
|
|
-
|
Gain
from discontinued operations
|
|
|
-
|
|
|
-
|
|
|
1,081,173
|
|
|
-
|
Net
Income (Loss)
|
|
$
|
(90,349)
|
|
$
|
16,905
|
|
$
|
1,531,480
|
|
$
|
(638,703)
|
Note
10. Discontinued Operations
On
June 22, 2017, the Company sold off its VitaCig operations. The Company was returned 172,500,000 shares of common stock of the
Company’s common stock, par value $0.0001 per share (“Common Stock”), from mCig, Inc., and was forgiven $68,123
in debt owed to MCIG in exchange for the VitaCig operations. The record date for the transaction was June 22, 2017. The
transaction was completed for the purpose of legally and structurally separating the VitaCig operation from the newly acquired
business and the Company’s change in direction.
The
selloff of VitaCig has been presented as discontinued operations in our financial statements. The following tables represent the
current assets and liabilities associated with the discontinued operations as of January 31, 2017:
Assets
Cash
|
|
$
|
44,280
|
Accounts
receivable
|
|
|
10,518
|
Prepaid
expenses
|
|
|
3,300
|
Inventory
|
|
|
26,607
|
Intangible
assets
|
|
|
1,343
|
Total
assets related to discontinued operations
|
|
$
|
86,048
|
Liabilities
Current
liabilities
|
|
|
12,974
|
Deferred
revenue
|
|
|
31,874
|
Due
to mCig payable
|
|
|
68,123
|
Due
to related party
|
|
|
2,000
|
Liabilities
related to discontinued operations
|
|
$
|
114,971
|
As
of January 31, 2017, the Company has recorded a gain of $1,081,173 for its discontinued operations. The following table presents
the net book value of VitaCig as of the selloff, the pro-rata value received as part of the selloff, and the net gain for the
selloff of the VitaCig operations:
Net
book value of VitaCig at sell-off
|
|
$
|
(28,923)
|
FMV
of stock received from sell-off
|
|
|
1,052,250
|
Net
gain from discontinued operations
|
|
$
|
1,081,173
|
Note
11. Basic Loss per Share
Basic
Income (Loss) Per Share
- The computation of basic and diluted loss per common share is based on the weighted average
number of shares outstanding during each period.
|
|
Three
Months Ended
|
|
|
January
31,
|
|
|
2017
|
|
2016
|
Net
income (loss)
|
|
$
|
(90,349
|
)
|
|
$
|
(24,040
|
)
|
Basic
income (loss) per share
|
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
Basic
weighted average number of shares outstanding
|
|
|
975,828,741
|
|
|
|
503,232,826
|
|
|
|
Nine
Months Ended
|
|
|
January
31,
|
|
|
2017
|
|
2016
|
Net
income (loss)
|
|
$
|
915,480
|
|
|
$
|
(110,657
|
)
|
Basic
income (loss) per share
|
|
$
|
0.00
|
|
|
$
|
(0.00
|
)
|
Basic
weighted average number of shares outstanding
|
|
|
888,232,826
|
|
|
|
501,683,913
|
|
The
computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during the periods.
Note
12. Subsequent Events
In
accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that
there are no additional material subsequent events to report.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Unless
otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our”
are to the Company, unless the context requires otherwise. The following discussion and analysis by our management of our financial
condition and results of operations should be read in conjunction with our unaudited condensed interim financial statements and
the accompanying related notes included in this quarterly report and our audited financial statements and related notes and Management’s
Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year
ended April 30, 2017 filed with the Securities and Exchange Commission.
Cautionary
Statement Regarding Forward-Looking Statements
This
report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking
statements are based on our management’s beliefs and assumptions and on information currently available to our management.
Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning
our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment,
potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical
facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,”
“expects,” “hopes,” “intends,” “may,” “plans,” “potential,”
“predicts,” “projects,” “should,” “will,” “would” or similar expressions.
Forward-looking
statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should
not place undue reliance on these forward-looking statements.
Also,
forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should
read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with
the understanding that our actual future results may be materially different from what we expect. Except as required by law, we
assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Additional
information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission,
including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended April 30, 2017.
Unless
otherwise indicated or the context otherwise requires, all references in this Form 10-Q to “we,” “us,”
“our,” “our company,” “VitaCig” or the “Company” refer to VitaCig, Inc.
Our
Ability to Continue as a Going Concern
Our
independent registered public accounting firm has issued its report dated January 31, 2017, in connection with the audit of our
annual financial statements as of April 30, 2017, that included an explanatory paragraph describing the existence of conditions
that raise substantial doubt about our ability to continue as a going concern and Note 3 to the unaudited financial statements
for the period ended January 31, 2017 also describes the existence of conditions that raise substantial doubt about our ability
to continue as a going concern.
O
verview
Corporate
History
We
were incorporated in Nevada on January 22, 2014. We began as a technology company that was engaged in the manufacturing
and retailing of nicotine-free Electronic Cigarettes (“eCigs”) that are pre-packaged with vitamins, nutrients, and
generic pharmaceuticals.
We
were originally formed as a wholly-owned subsidiary of mCig, Inc. On February 24, 2014, our company entered into a Contribution
Agreement with mCig, Inc. In accordance with this agreement we accepted the contribution by mCig, Inc. of specific assets
consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO and $500 in cash as contribution
in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of VitaCig, Inc.
On
November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc.
On
June 17, 2017 VitaCig acquired Malecon Pharmacy, Inc., in a Stock Exchange Agreement. VitaCig issued LX Retail Group, LLC 575,000,000
common shares of stock in exchange for 100% of the stock of Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., operates as a subsidiary
of VitaCig, Inc. Malecon Pharmacy is a premiere anti-aging cream manufacturer, wholesaler, and distributor.
On
June 22, 2017 VitaCig sold its eCig business element to mCig, Inc., in exchange for the return to treasury stock 172,500,000 shares
of VitaCig stock and the reduction of the outstanding amount owed by Vitacig, Inc., to mCig, Inc., the amount of
$122,394.
As a result of this transaction, VitaCig, Inc., became a holding company in which it has one wholly owned subsidiary, Malecon
Pharmacy, Inc.
On
August 9, 2017 the Company changed its name from “VitaCig, Inc.” to “Omni Health, Inc.”.
The
fiscal year end is April 30.
Our
Company
The
Company operates a pharmacy in Hialeah, Florida. All of our operations are conducted through our wholly-owned subsidiaries, Malecon
Pharmacy, Inc.
Malecon
Pharmacy, Inc., is a vertically integrated company focused on healthcare and operating in the highly lucrative pharmaceutical,
medical and wellness industries, since 1974. We are licensed provider of innovative health, wellness and pharmacy services through
our pharmacy located in Hialeah, Florida.
Governmental
Regulation
Our
business is subject to federal, state and local laws, regulations, and administrative practices, including, among others: federal,
state and local licensure and registration requirements concerning the operation of pharmacies and the practice of pharmacy; the
Health Insurance Portability and Accountability Act (HIPAA); the Patient Protection and Affordable Care Act and the Health Care
and Education Reconciliation Act of 2012 (collectively, the Health Reform Law); statutes and regulations of the FDA, the U.S.
Federal Trade Commission, the U.S. Drug Enforcement Administration and the U.S. Consumer Product Safety Commission, as well as
regulations promulgated by comparable state agencies concerning the sale, advertisement and promotion of the products we sell.
Below are descriptions of some of the various federal and state laws and regulations which may govern or impact our current and
planned operations.
Pharmacy
Regulation
Our
pharmacy operations are regulated by both individual states and the federal government. Every state has laws and regulations addressing
pharmacy operations, including regulations relating specifically to compounding pharmacy operations. These regulations generally
include licensing requirements for pharmacists, pharmacy technicians and pharmacies, as well as regulations related to compounding
processes, safety protocols, purity, sterility, storage, controlled substances, recordkeeping and regular inspections, among other
things. State rules and regulations are updated periodically, generally under the jurisdiction of individual state boards of pharmacy.
Failure to comply with the state pharmacy regulations of a particular state could result in a pharmacy being prohibited from operating
in that state, financial penalties and/or becoming subject to additional oversight from that state’s board of pharmacy.
In addition, many states are considering imposing, or have already begun to impose, more stringent requirements on compounding
pharmacies. If our pharmacy operations become subject to additional licensure requirements, are unable to maintain their required
licenses or if states place burdensome restrictions or limitations on pharmacies, our ability to operate could be limited.
Certain
provisions of the FDCA govern the preparation, handling, storage, marketing and distribution of pharmaceutical products. The Drug
Quality and Security Act of 2013 (DQSA) clarifies and strengthens the federal regulatory framework governing compounding pharmacies.
Title 1 of the DQSA, the Compounding Quality Act, modifies provisions of the Section 503A of the FDCA that were found to be unconstitutional
by the U.S. Supreme Court in 2002. In general, Section 503A provides that pharmacies are exempt from the provisions of the FDCA
requiring compliance with cGMP, labeling with adequate directions for use and FDA approval prior to marketing if the pharmacy
complies with certain other requirements. Among other things, to comply with Section 503A, a compounded drug must be compounded
by a licensed pharmacist for an identified individual patient on the basis of a valid prescription. Pharmacies may only compound
in limited quantities before receipt of a prescription for an individual patient and are subject to limitations on anticipatory
compounding for distribution, which generally permit anticipatory compounding only based on historical prescription volumes.
Confidentiality,
Privacy and HIPAA
Our
pharmacy operations involve the receipt, use and disclosure of confidential medical, pharmacy and other health-related information.
In addition, we use aggregated and blinded (anonymous) data for research and analysis purposes. The federal privacy regulations
under HIPAA are designed to protect the medical information of a healthcare patient or health plan enrollee that could be used
to identify the individual. Among other things, HIPAA limits certain uses and disclosures
of
protected health information and requires compliance with federal security regulations regarding the storage, utilization and
transmission of and access to electronic protected health information. The requirements imposed by HIPAA are extensive. In addition,
most states have enacted privacy and security laws that protect identifiable patient information that is not health-related. Further,
several states have enacted more protective and comprehensive pharmacy-related privacy legislation that not only applies to patient
records but also prohibits the transfer or use for commercial purposes of pharmacy data that identifies prescribers. These regulations
impose substantial requirements on covered entities and their business associates regarding the storage, utilization and transmission
of and access to personal health and non-health information. Many of these laws apply to our business.
Medicare
and Medicaid Reimbursement
Medicare
is a federally funded program that provides health insurance coverage for qualified persons age 65 or older and for some disabled
persons with certain specific conditions. State-funded Medicaid programs provide medical benefits to groups of low-income and
disabled individuals, some of whom may have inadequate or no medical insurance. Currently, most of our commercially available
formulations are sold in cash transactions and our customers may choose to seek reimbursement opportunities from Medicare, Medicaid
and other third parties to the extent that they exist. As part of our initiative, we work with third-party insurers, pharmacy
benefit managers and buying groups to offer patient-specific customizable compounded formulations at accessible prices. We plan
to continue to devote time and other resources to seek reimbursement and patient pay opportunities for these and other compounded
formulations and we have hired pharmacy billers to process certain existing reimbursement opportunities for certain formulations.
However, we may be unsuccessful in achieving these goals, as many third-party payors have imposed significant restrictions on
reimbursement for compounded formulations in recent years. Moreover, third-party payors, including Medicare, are increasingly
attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in
some cases, to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling
approval. Further, the Health Reform Law may have a considerable impact on the existing U.S. system for the delivery and financing
of health care and could conceivable have a material effect on our business. As a result, reimbursement from Medicare, Medicaid
and other third-party payors may never be available for any of our products or, if available, may not be sufficient to allow us
to sell the products on a competitive basis and at desirable price points.
To
the extent we obtain third-party reimbursement for our compounded formulations, we may become subject to Medicare, Medicaid and
other publicly financed health benefit plan regulations prohibiting kickbacks, beneficiary inducement and the submission of false
claims.
Critical
Accounting Policies and Estimates
Our
discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these
financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses. On an ongoing basis, we evaluate our estimates, including those related to uncollectible receivables, inventory
valuation, deferred compensation and contingencies.
We
base our estimates on historical performance and on various other assumptions that we believe to be reasonable under the circumstances.
These estimates allow us to make judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.
We
believe the following accounting policies are our critical accounting policies because they are important to the portrayal of
our financial condition and results of operations and they require critical management judgments and estimates about matters that
may be uncertain. If actual results or events differ materially from those contemplated by us in making these estimates,
our reported financial condition and results of operations for future periods could be materially affected.
Pharmacy
Services.
We sells prescription drugs directly through our mail service pharmacies, home delivery, and through our retail
pharmacy. We recognize revenues from prescription drugs sold by our mail service and home delivery and the retail pharmacy through
contracts where we are the principal using the gross method at the contract prices negotiated with
our
customers. Revenue from Pharmacy Services includes: (i) the portion of the price the customer pays directly to us, net of
any volume-related or other discounts paid back to the customer, (ii) the portion of the price paid to us in a national retail
pharmacy network through the customers insurance plan, and (iii) administrative payments from national retail pharmacy network
contracts for incentives and initiatives.
SEC
Staff Accounting Bulletin 104, “Revenue Recognition, corrected copy” ( “SAB 104”) provides the general
criteria for the timing aspect of revenue recognition, including consideration of whether: (i) persuasive evidence of an
arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the
buyer is fixed or determinable and (iv) collectability is reasonably assured. The Company has established the following revenue
recognition policies in accordance with SAB 104:
|
·
|
Revenues
generated from prescription drugs sold by mail service pharmacies are recognized when
the prescription is shipped. At the time of shipment, the Company has performed substantially
all of its obligations under its customer contracts and does not experience a significant
level of reshipments.
|
|
·
|
Revenues
generated from prescription drugs sold through national retail pharmacy network and associated
administrative fees are recognized at the point-of-sale, which is when the claim is adjudicated
by the online claims processing system.
|
We
determine whether we are the principal or agent for our national retail pharmacy network transactions using the indicators set
forth in Emerging Issues Task Force (“EITF”) Issue No. 99-19, “Reporting Revenue Gross as a Principal versus
Net as an Agent” on a contract by contract basis. In all of our current contracts, we have determined we are the principal
due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in establishing the price, changing
the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement
in the determination of product or service specifications and (v) having credit risk. Responsibilities under our customer
contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments
due to the retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the physician prior
to dispensing, suggesting clinically appropriate generic alternatives where appropriate and approving the prescription for dispensing.
Although we do not have credit risk with respect to Retail Co-Payments, management believes that all of the other indicators of
gross revenue reporting are present.
Drug
Discounts ~ We deduct from our revenues any discounts paid to our customers as required by EITF No. 01-9, “Accounting
for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products)” (“EITF 01-9”).
Retail
Pharmacy Segment
~ We recognize revenue from the sale of merchandise (other than prescription drugs) at the time the
merchandise is purchased by the retail customer. Revenue from the sale of prescription drugs is recognized at the time the prescription
is filled, which is or approximates when the retail customer picks up the prescription. Customer returns are not material. Revenue
generated from the performance of services is recognized at the time the services are performed.
Amounts
billed or collected in excess of revenue recognized are recorded as deferred revenue.
Results
of Operations
Our
operating results for the three months and nine months ended January 31, 2017 and 2016 are summarized as follows:
|
For
the Three Months Ended January 31,
|
|
2017
|
|
2016
|
Revenue
|
$
|
1,470,844
|
|
$
|
39,110
|
Cost
of Goods Sold
|
|
1,072,701
|
|
|
37,473
|
Gross
Profit
|
|
398,143
|
|
|
1,637
|
Expenses
|
|
447,646
|
|
|
25,677
|
Net
Income(Loss) from operations
|
|
(49,503)
|
|
|
(24,040)
|
|
For
the Nine Months Ended January 31,
|
|
2017
|
|
2016
|
Revenue
|
$
|
3,270,793
|
|
$
|
117,853
|
Cost
of Goods Sold
|
|
2,366,269
|
|
|
85,555
|
Gross
Profit
|
|
904,524
|
|
|
32,298
|
Expenses
|
|
926,667
|
|
|
142,955
|
Net
Income(Loss) from operations
|
|
(22,142)
|
|
|
(110,657)
|
Three
Months Ended January 31, 2017 Compared to Three Months Ended January 31, 2016
Revenue
Our
revenue from operations for the three months ended January 31, 2017 was $1,470,844 compared to $39,110, an increase of $1,431,734,
for the three months ended January 31, 2016. This increase is primarily due to an increase in sales upon the acquisition
of Malecon Pharmacy on June 22, 2017. Revenues consist primarily of results from the sales of prescription drugs, non-prescription
drugs, and specialty products and related accessories.
Cost
of Goods Sold
Our
cost of goods sold for the three months ended January 31, 2017 was $1,072,701 compared to $37,473 for the three months ended January
31, 2016. This increase is primarily due to the increase in sales.
Gross
Profit
Our
gross profit for the three months ended January 31, 2017 was $395,143 compared to $1,637 for the three months ended January 31,
2016. The gross profit of $395,143 for the three months ended January 31, 2017 represents approximately 27.1% as a percentage
of total revenue. The gross profit of $1,637 for the three months ended January 31, 2016 represents approximately 4.2% as a percentage
of total revenue. This increase in the gross profit percentage is primarily attributed to the pricing policies of the company’s
new subsidiary, Malecon Pharmacy.
Operating
Expenses
Our
operating expenses increased by $783,711 to $926,666 for the nine months ended January 31, 2017, from $142,955 for the nine months
ended January 31, 2016. The increase was primarily due to the increase in selling, general and administrative expenses of $152,738,
an increase in payroll of $187,080, an increase in consulting fees of $424,945, an increase in depreciation of $16,624, and in
professional fees of $2,325.
Our
total operating expenses for the nine months ended January 31, 2017 of $926,667 consisted of $275,843 of selling, general and
administrative expenses, $187,080 in payroll expenses, $21,075 in professional fees, $424,945 in consulting fees, and $17,724
in depreciation expenses. Our general and administrative expenses consist of salaries, bank charges, telephone expenses, meals
and entertainments, computer and internet expenses, postage and delivery, office supplies and other expenses.
Net
Income
Our
net loss increased by $25,463 to $49,503 for the three months ended January 31, 2017 compared to a net loss of $24,040 for the
three months ending January 31, 2016. The decrease in net income compared to the prior period is primarily a result of the increase
in operating expenses of $421,646 and the increase in gross profit of $393,506.
Nine
Months Ended January 31, 2017 Compared to Nine Months Ended January 31, 2016
Revenue
Our
revenue from operations for the nine months ended January 31, 2017 was $3,270,793 compared to $117,853, an increase of $3,152,940,
for the nine months ended January 31, 2016. This increase is primarily due to an increase in sales upon the acquisition
of Malecon Pharmacy on June 22, 2017. Revenues consist primarily of results from the sales of prescription drugs, non-prescription
drugs, and specialty products and related accessories.
Cost
of Goods Sold
Our
cost of goods sold for the nine months ended January 31, 2017 was $2,366,269 compared to $85,555 for the nine months ended January
31, 2016. This increase is primarily due to the increase in sales.
Gross
Profit
Our
gross profit for the nine months ended January 31, 2017 was $904,524 compared to $32,298 for the nine months ended January 31,
2016. The gross profit of $904,524 for the nine months ended January 31, 2017 represents approximately 27.7% as a percentage of
total revenue. The gross profit of $32,298 for the nine months ended January 31, 2016 represents approximately 27.4% as a percentage
of total revenue. This increase in the gross profit percentage is primarily attributed to the pricing policies of the company’s
new subsidiary, Malecon Pharmacy.
Operating
Expenses
Our
operating expenses increased by $783,711 to $926,666 for the nine months ended January 31, 2017, from $142,955 for the nine months
ended January 31, 2016. The increase was primarily due to the increase in selling, general and administrative expenses of $110,375,
an increase in payroll of $261,111, an increase in consulting fees of $371,988, an increase in depreciation of $16,624, and in
professional fees of $23,613.
Our
total operating expenses for the nine months ended January 31, 2017 of $926,666 consisted of $233,480 of selling, general and
administrative expenses, $261,111 in payroll expenses, $42,363 in professional fees, $371,988 in consulting fees, and $17,724
in depreciation expenses. Our general and administrative expenses consist of salaries, bank charges, telephone expenses, meals
and entertainments, computer and internet expenses, postage and delivery, office supplies and other expenses.
Net
Income
Our
net income increased by $1,026,137 to $915,480 for the nine months ended January 31, 2017 compared to a net loss of $110,657 for
the nine months ending January 31, 2016. The increase in net income compared to the prior period is primarily a result of the
increase in gain from discontinued operation of $1,081,173, the increase in operating expenses of $783,711, an increase in interest
expense of $143,551, and the increase in gross profit of $872,226.
Liquidity
and Capital Resources
Introduction
During
the nine months ended January 31, 2017 because of the acquisition of Malecon Pharmacy, we generated positive operating cash flows.
The net cash provided by operating activities was $601,701, and our cash and cash equivalents on hand as of January 31,
2017 was $7,649.
Cash
Requirements
We
had cash available of $7,649 as of January 31, 2017. Based on our revenues, cash on hand and current monthly burn rate,
we believe that our operations are sufficient to fund operations through April 2017.
Sources
and Uses of Cash
Operations
We
had net cash provided in operating activities of $601,701 for the nine months ended January 31, 2017, as compared to cash used
of $107,244 for the nine months ended January 31, 2016.
Net
cash provided in operations consisted primarily of the net income of $915,480. Changes in assets and liabilities consisted of
decreases in inventory of $3,006, accounts receivable of $95,460, an increase in other receivable of $146,700, and an increase
in accounts payable of $86,336.
Investments
We
had net cash received in investing activities of $1,601 for the nine months ended January 31, 2017 and $0 in cash used in investing
activities for the nine months ended January 31, 2016.
Financing
We
had net cash used in financing activities of $724,763 for the nine months ended January 31, 2017, as compared to net cash provided
of $87,693 for the nine months ended January 31, 2016. Our financing activities consisted primary of cash provided from
issuance of common stock of $98,109, cash used for loans with related parties of $427,276 and an increase of notes payable of
$656,744 (which consisted on $51,457 in long term loans and $605,197 in short term loans). As part of the discontinued operations,
the company purchased $1,052,250 of its company stock held in treasury.
Off-Balance
Sheet Arrangements
We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that we consider material.
Going
Concern
Our
financial statements are prepared using generally accepted accounting principles, which contemplate the realization of assets
and liquidation of liabilities in the normal course of business. Because the business is relatively new and has a short history
and relatively few sales, no certainty of continuation can be stated. The accompanying financial statements for the three months
and nine months ended January 31, 2017 and 2016 have been prepared assuming that we will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business.
The
Company has incurred losses from operations and has a working capital deficit, which raises substantial doubt about its ability
to continue as a going concern